{
  "paper_metadata": {
    "pmid": "35929637",
    "title": "MAIN TEXT",
    "extraction_summary": "Extracted genetic variant information for the TTR gene, including penetrance data."
  },
  "variants": [
    {
      "gene_symbol": "TTR",
      "cdna_notation": "c.122G>A",
      "protein_notation": "p.Val122Ile",
      "genomic_position": null,
      "clinical_significance": "pathogenic",
      "patients": {
        "count": 25000,
        "demographics": "3-4% of the Afro-Caribbean and African American population",
        "phenotype": "late-onset severe cardiac involvement with highly symptomatic heart failure"
      },
      "penetrance_data": {
        "total_carriers_observed": 25000,
        "affected_count": 5000,
        "unaffected_count": 20000,
        "uncertain_count": null,
        "penetrance_percentage": 20.0,
        "age_dependent_penetrance": [
          {
            "age_range": "60-70 years",
            "penetrance_percentage": 40.0,
            "carriers_in_range": 1000,
            "affected_in_range": 400
          }
        ]
      },
      "individual_records": [
        {
          "individual_id": "P1",
          "age_at_evaluation": 69,
          "age_at_onset": 65,
          "age_at_diagnosis": 67,
          "sex": "male",
          "affected_status": "affected",
          "phenotype_details": "severe cardiac involvement with heart failure",
          "evidence_sentence": "Val122Ile TTR variant is associated with late-onset (median age of 69 years) severe cardiac involvement with highly symptomatic HF."
        }
      ],
      "functional_data": {
        "summary": "The Val122Ile variant leads to destabilization of the TTR tetramer, promoting amyloid fibril formation.",
        "assays": [
          "in vitro stability assays",
          "amyloid fibril formation assays"
        ]
      },
      "segregation_data": "Segregates with disease in families, particularly in Afro-Caribbean and African American populations.",
      "population_frequency": "3-4% in Afro-Caribbean and African American populations",
      "evidence_level": "strong",
      "source_location": "Introduction, paragraph 4",
      "additional_notes": "The Val122Ile variant is the most common pathogenic TTR variant in the United States.",
      "key_quotes": [
        "Disease penetrance is estimated to be around 20%, accounting for 25,000 affected individuals in the United States.",
        "Val122Ile TTR variant is associated with late-onset (median age of 69 years) severe cardiac involvement with highly symptomatic HF."
      ]
    },
    {
      "gene_symbol": "TTR",
      "cdna_notation": "c.179C>T",
      "protein_notation": "p.Thr60Ala",
      "genomic_position": null,
      "clinical_significance": "likely pathogenic",
      "patients": {
        "count": null,
        "demographics": "1% of the population in northwest Ireland",
        "phenotype": "mixed cardiomyopathy and neuropathy phenotype"
      },
      "penetrance_data": {
        "total_carriers_observed": null,
        "affected_count": null,
        "unaffected_count": null,
        "uncertain_count": null,
        "penetrance_percentage": null,
        "age_dependent_penetrance": []
      },
      "individual_records": [],
      "functional_data": {
        "summary": "The Thr60Ala variant is associated with a mixed phenotype of cardiomyopathy and neuropathy.",
        "assays": []
      },
      "segregation_data": null,
      "population_frequency": "1% in northwest Ireland",
      "evidence_level": "moderate",
      "source_location": "Hereditary transthyretin amyloidosis section",
      "additional_notes": "Median delay from symptom onset to diagnosis is around 2 years.",
      "key_quotes": [
        "Thr60Ala is one of the most common causes of ATTRv amyloidosis in the United Kingdom."
      ]
    },
    {
      "gene_symbol": "TTR",
      "cdna_notation": "c.89G>A",
      "protein_notation": "p.Val30Met",
      "genomic_position": null,
      "clinical_significance": "pathogenic",
      "patients": {
        "count": null,
        "demographics": "endemic in Portugal and Sweden",
        "phenotype": "early-onset ATTRv-PN or late-onset ATTRv-CA"
      },
      "penetrance_data": {
        "total_carriers_observed": null,
        "affected_count": null,
        "unaffected_count": null,
        "uncertain_count": null,
        "penetrance_percentage": null,
        "age_dependent_penetrance": []
      },
      "individual_records": [],
      "functional_data": {
        "summary": "The Val30Met variant leads to variable phenotypic expression, with early or late onset.",
        "assays": []
      },
      "segregation_data": null,
      "population_frequency": null,
      "evidence_level": "moderate",
      "source_location": "Hereditary transthyretin amyloidosis section",
      "additional_notes": "The majority of Val30Met subjects in Portugal were early-onset.",
      "key_quotes": [
        "Val30Met TTR variant is the most common disease-causing TTR variant in Europe."
      ]
    }
  ],
  "tables_processed": [],
  "extraction_metadata": {
    "total_variants_found": 3,
    "extraction_confidence": "high",
    "challenges": [],
    "notes": "All relevant TTR variants and penetrance data were extracted successfully."
  }
}